Optic nerve haemangioblastomas remain exceedingly rare extrinsic tumours of the optic nerve, often associated with von Hippel-Lindau disease. The authors report a 25-year-old female with a slowly progressive unilateral optic nerve lesion, causing reduced vision and bilateral optic tract oedema. A diagnosis of optic nerve haemangioblastoma with piloid gliosis was made histologically after surgical resection. This is the first reported case of such dual pathology occurring in the optic nerve. The patient has been monitored without further adjuvant treatment, and has not had a recurrence to date, at 6 years of follow-up.

Keywords:
Optic nerve, Haemangioblastoma, von Hippel-Lindau, Piloid gliosis
1.
Miller NR: Primary tumours of the optic nerve and its sheath. Eye (Lond) 2004; 18: 1026–1037.
2.
Zywicke H, Palmer CA, Vaphiades MS, et al: Optic nerve hemangioblastoma: a case report. Case Rep Pathol 2012; 2012: 915408.
3.
Raila FA, Zimmerman J, Azordegan P, et al: Successful surgical removal of an asymptomatic optic nerve hemangioblastoma in von Hippel-Lindau disease. J Neuroimaging 1997; 7: 48–50.
4.
Singh AD, Shields CL, Shields JA: von Hippel-Lindau disease. Surv Ophthalmol 2001; 46: 117–142.
5.
Ammerman JM, Lonser RR, Dambrosia J, et al: Long-term natural history of hemangioblastomas in patients with von Hippel-Lindau disease: implications for treatment. J Neurosurg 2006; 105: 248–255.
6.
Hotta H, Uede T, Morimoto S, et al: Optic nerve hemangioblastoma. Case report. Neurol Med Chir (Tokyo) 1989; 29: 948–952.
7.
Maher ER, Yates JR, Ferguson-Smith MA: Statistical analysis of the two stage mutation model in von Hippel-Lindau disease, and in sporadic cerebellar haemangioblastoma and renal cell carcinoma. J Med Genet 1990; 27: 311–314.
8.
Webster ER, Richards FM, MacRonald FE, et al: An analysis of phenotypic variation in the familial cancer syndrome von Hippel-Lindau disease: evidence for modifier effects. Am J Hum Genet 1998; 63: 1025–1035.
9.
Ginzburg BM, Montanera WJ, Tyndel FJ, et al: Diagnosis of von Hippel-Lindau disease in a patient with blindness resulting from bilateral optic nerve hemangioblastomas. AJR Am J Roentgenol 1992; 159: 403–405.
10.
Fons Martinez MR, Espana Gregori E, Avino Martinez JA, et al: An optic nerve tumor in von Hippel-Lindau disease, masquerading as a retinal hemangioma (in Spanish). Arch Soc Esp Oftalmol 2006; 81: 293–296.
11.
Meyerle CB, Dahr SS, Wetjen NM, et al: Clinical course of retrobulbar hemangioblastomas in von Hippel-Lindau disease. Ophthalmology 2008; 115: 1382–1389.
12.
Kouri JG, Chen MY, Watson JC, et al: Resection of suprasellar tumors by using a modified transsphenoidal approach. Report of four cases. J Neurosurg 2000; 92: 1028–1035.
13.
Turel MK, Kucharczyk W, Gentili F: Optic nerve hemangioblastomas – a review of visual outcomes. Turk Neurosurg 2016; 27: 827–831.
14.
Baggenstos M, Chew E, Butman JA, et al: Progressive peritumoral edema defining the optic fibers and resulting in reversible visual loss. J Neurosurg 2008; 109: 313–317.
15.
Wanebo JE, Lonser RR, Glenn GM, et al: The natural history of hemangioblastomas of the central nervous system in patients with von Hippel-Lindau disease. J Neurosurg 2003; 98: 82–94.
16.
Rivera-Zengotita M, Yachnis AT: Gliosis versus glioma?: don’t grade until you know. Adv Anat Pathol 2012; 19: 239–249.
17.
Grattarola FR: Piloid gliosis; a histological study. J Neuropathol Exp Neurol 1958; 17: 644–648.
18.
Konig A, Laas R, Muller D: Three cases of intramedullary spinal hemangioblastoma: the role of intraoperative histological diagnosis. Neurosurg Rev 1987; 10: 153–155.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.